Novel Therapeutic Compounds for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly primary open-angle glaucoma, face challenges in effectively reducing intraocular pressure due to obstruction of aqueous humor outflow, with existing eicosanoids and their derivatives showing limitations in managing the condition.
Innovation Solution
Development of novel compounds with specific structural features, including organic acid functional groups, amides, esters, hydroxymethyl, or tetrazolyl functional groups, which serve as bioisosteres of carboxylic acids, to enhance ocular hypotensive effects and improve drainage of aqueous humor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional eicosanoids and their derivatives are used for glaucoma management, then ocular hypotensive effects are achieved, but efficacy is limited due to obstruction of aqueous humor outflow
Solution Approach 1:
The patent modifies the chemical structure of traditional eicosanoids by introducing bioisosteric replacements (such as tetrazole groups replacing carboxylic acid groups) and structural variations in the side chains and cyclic moieties. These parameter changes in molecular structure aim to enhance the compounds' ability to overcome the obstruction of aqueous humor outflow and improve their ocular hypotensive efficacy.
Solution Approach 2:
The invention creates composite molecular structures by combining modified eicosanoid cores with various substituent groups including aryl, heteroaryl, and alkyl chains with specific functional groups. These composite structures are designed to optimize both the pharmacological activity and the ability to navigate through the obstructed aqueous humor drainage pathway.
2Reliability
If novel compounds with bioisosteric groups are developed, then biological activity is enhanced, but structural complexity increases
Solution Approach 1:
The patent applies local quality modifications by introducing specific functional groups (such as tetrazole, hydroxymethyl, ether groups) at particular positions on the eicosanoid molecular framework. Rather than completely redesigning the entire molecule, the invention makes targeted local modifications to specific regions of the molecule to enhance biological activity while maintaining the core structural simplicity.
Solution Approach 2:
The invention systematically varies parameters such as the length of alkyl chains, the position of double bonds, the type of aromatic substituents, and the nature of functional groups to optimize biological activity. These controlled parameter changes allow for structure-activity relationship optimization without requiring complete structural redesign.
Data Source
AI summary
Disclosed herein is a compound having a structureor a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.